Drug Profile
Interferon beta-1b biosimilar - Primrose Bio
Alternative Names: PF 530Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Pfenex - Stelis Biopharma (JV)
- Developer Primrose Bio
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 28 Jul 2018 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Australia (SC, Injection)